Edward Garmey

Edward Garmey has a long history of experience in the medical oncology field. Edward began their career in 2014 as a Visiting Instructor in the Therapeutics Graduate Program at Harvard Medical School. In 2018, they founded CMO Consulting, Inc., providing integrated, strategic, and comprehensive clinical drug development consulting services to the biopharmaceutical industry. Since then, they have served as a Consultant Chief Medical Officer for ImmunoSensor Therapeutics (2019), Linnaeus Therapeutics (2020), Oncoheroes Biosciences (2021), and GigaGen Inc. (2021). In 2022, they began working as a Consulting CMO for Tagworks Pharmaceuticals, ModeX Therapeutics Inc, and ImmunoMet Therapeutics, Inc., and as an Interim CMO for HiFiBiO Therapeutics.

Edward Garmey received their AB from Harvard University and their M.D. from the Icahn School of Medicine at Mount Sinai.